Sage Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results. Additionally, HC Wainwright & Co. Cut Its Price Target on the Stock From $25 to $14.
Sage Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results. Additionally, HC Wainwright & Co. Cut Its Price Target on the Stock From $25 to $14.
sage therapeutics股價下跌，因公司報告的Q3每股收益結果低於預期。此外，HC Wainwright & Co.將該股票的目標價從25美元降至14美元。
Sage Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results. Additionally, HC Wainwright & Co. Cut Its Price Target on the Stock From $25 to $14.
sage therapeutics股價下跌，因公司報告的Q3每股收益結果低於預期。此外，HC Wainwright & Co.將該股票的目標價從25美元降至14美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間